<DOC>
	<DOCNO>NCT02052687</DOCNO>
	<brief_summary>The purpose first-in human study demonstrate systemic local tolerability investigate pharmacokinetics LFX453 multiple topical application healthy subject . The current study design three distinct part . Part 1 focus safety tolerability daily application back , prior move forward assess safety tolerability sensitive treatment area Part 2 twice daily application Part 3 .</brief_summary>
	<brief_title>A First-in-human Study Evaluate Safety , Tolerability Pharmacokinetics LFX453</brief_title>
	<detailed_description />
	<mesh_term>Imiquimod</mesh_term>
	<criteria>Healthy male female subject nonchildbearing potential , 18 65 year age inclusive ( time screen visit ) , good health determine past medical history , physical examination , vital sign , electrocardiogram , laboratory test screen . Male subject must agree total abstinence male : female intercourse agree use condom drug dose four week dose stop . History serious allergic reaction drug . History hypersensitivity study drug drug similar chemical class . History atopic dermatitis ( within last 2 year ) , autoimmune disease , psoriasis erythema multiforme . Presence skin disease ( e.g . wart ) skin feature treatment area may affect local tolerability ability investigator evaluate local tolerability . History heart failure , leave ventricular dysfunction know family history know presence long QT syndrome . A history clinically significant ECG abnormality , follow ECG abnormality screen baseline : 2nd 3rd degree AVblock PR &gt; 200 msec QRS complex &gt; 120 msec QTcF &gt; 450 msec ( male ) QTcF &gt; 460 msec ( female ) Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive hCG laboratory test . Women childbearing potential , defined woman physiologically capable become pregnant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Healthy volunteer</keyword>
</DOC>